QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $45
UBS Initiates Qiagen NV(QGEN.US) With Hold Rating
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 33% Undervaluation?
Baird Maintains Qiagen NV(QGEN.US) With Hold Rating, Raises Target Price to $43
Express News | Baird Maintains Neutral on Qiagen, Raises Price Target to $43
Qiagen Analyst Ratings
Trump Signs Executive Order on Drug Pricing
Market Chatter: Qiagen Holds Talks With Fivespan as Activist Investor Builds Stake
Express News | Watching Qiagen N.V.; Hearing Fivespan Is Said To Build Stake In Life Sciences Group Qiagen
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials Driving The Negative Sentiment?
QIAGEN To Launch Three New Sample Prep Instruments By 2026, Expanding Automation From Low To High Throughput Labs
BofA Securities Maintains Qiagen NV(QGEN.US) With Buy Rating, Cuts Target Price to $50
Life Sciences Companies Likely to See Surprisingly Good 1Q Results -- Market Talk
BofA Securities Cuts Price Target on Qiagen to $50 From $55, Maintains Buy Rating
QIAGEN's QCI Interpret One Selected By Royal Marsden NHS Foundation Trust To Expand Marsden360 Liquid Biopsy Service For ESR1 Testing For Breast Cancer Patients
Research Alert: CFRA Keeps Hold Opinion On Shares Of Qiagen N.v.
UBS Maintains Qiagen NV(QGEN.US) With Hold Rating
William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating